[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aardvark Therapeutics Inc (AARD)

Aardvark Therapeutics Inc (AARD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,988
  • Shares Outstanding, K 21,884
  • Annual Sales, $ 0 K
  • Annual Income, $ -57,590 K
  • EBIT $ -75 M
  • EBITDA $ -76 M
  • 60-Month Beta 3.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.30

Options Overview Details

View History
  • Implied Volatility 232.30% (-32.26%)
  • Historical Volatility 82.58%
  • IV Percentile 15%
  • IV Rank 11.78%
  • IV High 913.51% on 03/11/26
  • IV Low 141.35% on 01/26/26
  • Expected Move (DTE 15) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 2.30
  • Today's Open Interest 1,715
  • Open Int (30-Day) 1,534
  • Expected Range 5.62 to 5.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.86
  • Number of Estimates 8
  • High Estimate $-0.51
  • Low Estimate $-1.06
  • Prior Year $-0.66
  • Growth Rate Est. (year over year) -30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.40 +65.29%
on 06/11/26
5.99 -6.18%
on 07/01/26
+1.63 (+40.85%)
since 06/01/26
3-Month
3.40 +65.29%
on 06/11/26
6.79 -17.23%
on 05/14/26
+1.53 (+37.41%)
since 04/01/26
52-Week
3.35 +67.76%
on 03/27/26
17.94 -68.67%
on 10/08/25
-7.94 (-58.55%)
since 07/01/25

Most Recent Stories

More News
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS

SAN FRANCISCO , June 25, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 5.62 (-2.43%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

NEW YORK , June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are...

AARD : 5.62 (-2.43%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD).  Such investors...

AARD : 5.62 (-2.43%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS

SAN FRANCISCO , May 28, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 5.62 (-2.43%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are...

AARD : 5.62 (-2.43%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS

SAN FRANCISCO , May 21, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 5.62 (-2.43%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

SAN FRANCISCO , May 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 5.62 (-2.43%)
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule...

AARD : 5.62 (-2.43%)
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman

SAN FRANCISCO , May 7, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics ( NASDAQ: AARD ) saw the price of their shares crater $7.02 (-56%) after the company announced...

AARD : 5.62 (-2.43%)
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations...

AARD : 5.62 (-2.43%)

Business Summary

Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 6.68
2nd Resistance Point 6.33
1st Resistance Point 5.98
Last Price 5.62
1st Support Level 5.28
2nd Support Level 4.93
3rd Support Level 4.58

See More

52-Week High 17.94
Fibonacci 61.8% 12.37
Fibonacci 50% 10.65
Fibonacci 38.2% 8.92
Last Price 5.62
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.